Dr. Lepore joined Aquestive in December of 2020. Prior to joining Aquestive, Dr. Lepore was the Vice President of Global Clinical Strategy and Development for Lupin. In that role he led all clinical activities for inhalation drug-device and complex injectable products, with a focus on the U.S. and Europe. From 2008 to 2013, Dr. Lepore held various roles at Teva, where he helped develop several 505(b)(2) inhaled drug-device products, including Proair Respiclick, Airduo Respiclick, and for Europe, Duoresp Spiromax. Prior to 2008, Dr. Lepore was a partner, practicing physician, and clinical researcher with Allergy and Asthma Specialists in Blue Bell, Pennsylvania. During his time in practice, Dr. Lepore contributed to over 100 industry-sponsored clinical trials. Dr. Lepore received his BS degree in Biology from St. Joseph’s University in Philadelphia, and his MD from Jefferson Medical College of Thomas Jefferson University in Philadelphia. He completed his residency in Pediatrics at University of Maryland Medical System, and his fellowship in Allergy/Clinical Immunology at Cincinnati Children’s Hospital Medical Center. Dr. Lepore has board certified both in General Pediatrics and Allergy/Clinical Immunology, and is a Fellow of the American Academy of Allergy, Asthma, and Immunology.